Compare ARQT & BKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARQT | BKV |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | 452 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 2020 | N/A |
| Metric | ARQT | BKV |
|---|---|---|
| Price | $28.36 | $23.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $34.00 | ★ $34.22 |
| AVG Volume (30 Days) | ★ 1.3M | 716.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $376,072,000.00 | N/A |
| Revenue This Year | $34.85 | $69.39 |
| Revenue Next Year | $29.39 | $9.45 |
| P/E Ratio | ★ N/A | $57.07 |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $13.70 | $19.56 |
| 52 Week High | $31.77 | $32.81 |
| Indicator | ARQT | BKV |
|---|---|---|
| Relative Strength Index (RSI) | 60.62 | 32.14 |
| Support Level | $27.63 | $23.55 |
| Resistance Level | $29.47 | $27.99 |
| Average True Range (ATR) | 1.19 | 0.96 |
| MACD | -0.13 | -0.18 |
| Stochastic Oscillator | 63.19 | 0.27 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
BKV Corp is a growth-driven energy company focused on the development of natural gas-producing assets, the ownership and operation of natural gas-fired power generation assets, and selective accretive acquisitions. The company's core businesses are the production of natural gas and the generation of natural gas-fired power from its owned and operated assets, supported by a closed-loop plan, enabled by its upstream, midstream, power, and CCUS businesses.